Stellar(US) | $2,700,000 | (Jan 9, 2025)
XyloCor Therapeutics, Inc. | $67,500,000 | (Jan 9, 2025)
Aspect Biosystems | $115,000,000 | (Jan 9, 2025)
Coave Therapeutics
France
- PARIS
- 09/01/2025
- Series A
- $32,000,000
Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases.
We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases.
Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.
- Industry Biotechnology Research
- Website https://coavetx.com/
- LinkedIn https://www.linkedin.com/company/coavetx/
Related People
Rodolphe ClervalFounder
France -
Paris, Île-de-France
Biotech industry executive with 20 years of experience in strategy, business development and corporate finance.
Relief Cardiovascular | $12,000,000 | (Jan 9, 2025)
VitVio | $2,000,000 | (Jan 9, 2025)
Qualified Health | $30,000,000 | (Jan 9, 2025)
Evergreen Nephrology | $130,000,000 | (Jan 9, 2025)
UNLISTED | $2,250,000 | (Jan 9, 2025)
Zeto / Rapid Full-Montage EEG | $31,000,000 | (Jan 9, 2025)
Red Rover Health, Inc. | $4,000,000 | (Jan 9, 2025)
Deep Vector | $1,500,000 | (Jan 9, 2025)
Ubiety Technologies, Inc. | $10,000,000 | (Jan 9, 2025)